Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a revolving credit facility in the amount of $5,000,000. Reliv International, Inc (NASDAQ:RELV) stock performance was -5.17% in last session and finished the day at $2.20. Traded volume was 26,978.00million shares in the last session and the average volume of the stock remained 15.85K shares. The beta of the stock remained 1.60. Reliv International, Inc (NASDAQ:RELV) insider ownership is 0.20%.

Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. Ocera Therapeutics Inc (NASDAQ:OCRX) dropped -5.04 percent to $10.56 Wednesday on volume of 84,085.00million shares. The intra-day range of the stock was $10.32 to $11.45. Ocera Therapeutics Inc (NASDAQ:OCRX) has a market capitalization of $163.19million.

On March 28, 2014 (Japanese Standard Time), MediciNova, Inc. (NASDAQ:MNOV) filed with the Tokyo Stock Exchange a Japanese report referred to as “Kessan Tanshin,” which contained the Company’s financial results for the year ended December 31, 2013 (the “Tanshin”). MediciNova, Inc. (NASDAQ:MNOV)’s stock on Apr 02, 2014 reported a decrease of -5.41% to the closing price of $2.10. Its fifty two weeks range is $1.91 -$5.25. The total market capitalization recorded $47.04million. The overall volume in the last trading session was 98,944.00million shares. In its share capital, MNOV has 24.08million outstanding shares.

PTC Therapeutics (NASDAQ:PTCT) CEO Stuart Walter Peltz sold 25,487 shares of the company’s stock on the open market in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $29.86, for a total value of $761,041.82. Following the sale, the chief executive officer now directly owns 135,902 shares of the company’s stock, valued at approximately $4,058,034. On Wednesday, shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) dropped -7.31% to close the day at $25.10. Company return on investment (ROI) is -33.30% and its monthly performance is recorded as -25.87%. PTC Therapeutics, Inc. (NASDAQ:PTCT) quarterly revenue growth is 47.91%.